DavidTBowenMD

PubMed

• 20 citations
  Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome
  Hege Garelius, W.T. Johnston, Alexandra Smith, Sophie Park, L. de Swart, Pierre Fenaux, Argiris Symeonidis, Guillermo Sanz, Jaroslav Cermak, Reinhard Stauder, Luca Mal...> ;Journal of Internal Medicine. 2017 Mar 1
• Time-dependent changes in mortality and transformation risk in MDS.
  Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cerm...> ;Blood. 2016-08-18
• Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
  Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola ...> ;Blood. 2016-08-17
• 5 citations
  Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes.
  Francesca Mastaglio, Khaled Bedair, Elli Papaemmanuil, Michael J. Groves, Ann Hyslop, Norene Keenan, Eleanor J Hothersall, Peter J. Campbell, David T. Bowen, Sudhir Tauro> ;British Journal of Haematology. 2016 Apr 20
• 227 citations
  Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia
  Michael Andreeff, Kevin R. Kelly, Karen W.L. Yee, Sarit Assouline, Roger Strair, Leslie Popplewell, David G. Bowen, Giovanni Martinelli, Mark Drummond, Paresh Vyas, Ma...> ;Clinical Cancer Research. 2016 Feb 15
• 129 citations
  Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.
  Catherine Cargo, Nicola J. Rowbotham, Paul Evans, Sharon Barrans, David T. Bowen, Simon Crouch, Andrew Jack> ;Blood. 2015 Nov 19
• Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
  Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Bu...> ;Lancet Oncol.. 2015-11-01
• 335 citations
  Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
  Alan Kenneth Burnett, Nigel H. Russell, Robert Kerrin Hills, David T. Bowen, Jonathan Kell, Steven Knapper, Yvonne G Morgan, Jennie Lok, Angela Grech, Gail Jones, Asim...> ;The Lancet. Oncology. 2015 Oct 1
• Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective Europea...
  de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, Symeonidis A, Sanz G, Hellström-Lindberg E, Cermák J, Germing U, Stauder R, Georgescu O, MacKenzie M, Ma...> ;Br. J. Haematol.. 2015-08-01
• Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring ...
  Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak...> ;Leukemia. 2015-07-01
• Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.
  Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D, Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G, Jonasova A, Buc...> ;Br. J. Haematol.. 2015-02-01
• Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset an...
  Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, Selleslag D, Beyne-Rauzy O, te Boekhorst P, del Cañizo C, Guerci-Bresler A, Nilsson L, Lübbert M, ...> ;Eur. J. Haematol.. 2014-11-01
• Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction che...
  de Witte TM, Bowen D, Robin M, Malcovati L, Mufti G, Niederwieser D, Yakoubagha I, Kröger N> ;Clin Lymphoma Myeloma Leuk. 2014-09-01
• A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia.
  Drummond MW, Pocock C, Boissinot M, Mills J, Brown J, Cauchy P, Cross NCP, Hartley S, Kell J, Szubert A, Cockerill PN, Bowen DT> ;Leukemia. 2014-07-01
• Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.
  Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Gianno...> ;Cancer Cell. 2014-06-16
• p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).
  Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Göhring G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backst...> ;Haematologica. 2014-06-01
• Guidelines for the diagnosis and management of adult myelodysplastic syndromes.
  Killick SB, Carter C, Culligan D, Dalley C, Das-Gupta E, Drummond M, Enright H, Jones GL, Kell J, Mills J, Mufti G, Parker J, Raj K, Sternberg A, Vyas P, Bowen D> ;Br. J. Haematol.. 2014-02-01
• 6 citations
  Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients
  David T. Bowen, Eva Hellström-Lindberg, David P. Steensma> ;British Journal of Haematology. 2014 Feb 1
• 1302 citations
  Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
  Jyoti Nangalia, Charles E. Massie, E J Baxter, Francesca L. Nice, Gunes Gundem, David C. Wedge, Edward Avezov, Juan Li, Karoline Kollmann, David G. Kent, Athar Aziz, A...> ;The New England Journal of Medicine. 2013 Dec 19
• Clinical and biological implications of driver mutations in myelodysplastic syndromes.
  Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mud...> ;Blood. 2013-11-21
• Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
  Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbe...> ;Blood. 2013-10-24
• 110 citations
  Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
  Alan Kenneth Burnett, Nigel H. Russell, Ann Hunter, Donald Milligan, Steven Knapper, Keith Wheatley, John A. Liu Yin, Mary Frances McMullin, Sahra Ali, David T. Bowen,...> ;Blood. 2013 Aug 22
• 11 citations
  High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
  Fabio G. Liberante, Andrea Pellagatti, Viktoriya Bogdanova Boncheva, David T. Bowen, Ken I. Mills, Jacqueline Boultwood, Barbara-Ann Guinn> ;British Journal of Haematology. 2013 Jul 1
• 4 citations
  Azacitidine‐eligibility in higher‐risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry‐based study
  Senthilkumar Durairaj, Norene Keenan, Ann Hyslop, Michael J. Groves, David T. Bowen, Sudhir Tauro> ;British Journal of Haematology. 2013 Apr 1
• Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European Leu...
  van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SSC, Cullen M, Cutler ...> ;Leuk. Lymphoma. 2013-03-01
• Join now to see all